BioLight Life Sciences Ltd
Buy, Hold or Sell?
Let's analyse BioLight Life Sciences Ltd together
I guess you are interested in BioLight Life Sciences Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of BioLight Life Sciences Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
You can find me behind Let's Analyse Together in the top-right of each section.
Get notifications about BioLight Life Sciences Ltd
I send you an email if I find something interesting about BioLight Life Sciences Ltd.
Quick analysis of BioLight Life Sciences Ltd (30 sec.)
What can you expect buying and holding a share of BioLight Life Sciences Ltd? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
1. Valuation of BioLight Life Sciences Ltd (5 min.)
ILA565.00
ILA1,173.28
ILA-756.02 - ILA996.51
ILA417.26 - ILA2,169.79
2. Growth of BioLight Life Sciences Ltd (5 min.)
Is BioLight Life Sciences Ltd growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $13.9m | $15.9m | -$2m | -14.4% |
How much money is BioLight Life Sciences Ltd making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$2m | $99.1k | -$2.1m | -104.9% |
Net Profit Margin | -12,455.6% | 12,733.3% | - | - |
How much money comes from the company's main activities?
3. Financial Health of BioLight Life Sciences Ltd (5 min.)
4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
What can you expect buying and holding a share of BioLight Life Sciences Ltd? (5 min.)
Welcome investor! BioLight Life Sciences Ltd's management wants to use your money to grow the business. In return you get a share of BioLight Life Sciences Ltd.
What can you expect buying and holding a share of BioLight Life Sciences Ltd?
First you should know what it really means to hold a share of BioLight Life Sciences Ltd. And how you can make/lose money.
Speculation
The Price per Share of BioLight Life Sciences Ltd is ILA565.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of BioLight Life Sciences Ltd.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in BioLight Life Sciences Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA1,173.28. Based on the TTM, the Book Value Change Per Share is ILA-168.81 per quarter. Based on the YOY, the Book Value Change Per Share is ILA28.63 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
ILA | % of Price per Share | ILA | % of Price per Share | ILA | % of Price per Share | ILA | % of Price per Share | ILA | % of Price per Share | |
Usd Eps | -0.45 | -0.1% | -0.45 | -0.1% | 0.02 | 0.0% | 0.36 | 0.1% | -0.39 | -0.1% |
Usd Book Value Change Per Share | -0.44 | -0.1% | -0.44 | -0.1% | 0.07 | 0.0% | 0.52 | 0.1% | 0.09 | 0.0% |
Usd Dividend Per Share | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% |
Usd Total Gains Per Share | -0.44 | -0.1% | -0.44 | -0.1% | 0.07 | 0.0% | 0.52 | 0.1% | 0.09 | 0.0% |
Usd Price Per Share | 1.77 | - | 1.77 | - | 3.00 | - | 2.46 | - | 5.10 | - |
Price to Earnings Ratio | -3.97 | - | -3.97 | - | 138.25 | - | 25.87 | - | 9.50 | - |
Price-to-Total Gains Ratio | -4.03 | - | -4.03 | - | 40.31 | - | 5.71 | - | 5.34 | - |
Price to Book Ratio | 0.58 | - | 0.58 | - | 0.86 | - | 0.67 | - | 3.60 | - |
Price-to-Total Gains Ratio | -4.03 | - | -4.03 | - | 40.31 | - | 5.71 | - | 5.34 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 1.46674 |
Number of shares | 681 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.00 | 0.00 |
Usd Book Value Change Per Share | -0.44 | 0.52 |
Usd Total Gains Per Share | -0.44 | 0.52 |
Gains per Quarter (681 shares) | -298.43 | 352.79 |
Gains per Year (681 shares) | -1,193.72 | 1,411.17 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 0 | -1194 | -1204 | 0 | 1411 | 1401 |
2 | 0 | -2387 | -2398 | 0 | 2822 | 2812 |
3 | 0 | -3581 | -3592 | 0 | 4234 | 4223 |
4 | 0 | -4775 | -4786 | 0 | 5645 | 5634 |
5 | 0 | -5969 | -5980 | 0 | 7056 | 7045 |
6 | 0 | -7162 | -7174 | 0 | 8467 | 8456 |
7 | 0 | -8356 | -8368 | 0 | 9878 | 9867 |
8 | 0 | -9550 | -9562 | 0 | 11289 | 11278 |
9 | 0 | -10743 | -10756 | 0 | 12701 | 12689 |
10 | 0 | -11937 | -11950 | 0 | 14112 | 14100 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 0.0 | 1.0 | 0.0 | 0.0% | 1.0 | 2.0 | 0.0 | 33.3% | 2.0 | 3.0 | 0.0 | 40.0% | 2.0 | 8.0 | 0.0 | 20.0% | 3.0 | 8.0 | 5.0 | 18.8% |
Book Value Change Per Share | 0.0 | 1.0 | 0.0 | 0.0% | 1.0 | 2.0 | 0.0 | 33.3% | 2.0 | 3.0 | 0.0 | 40.0% | 4.0 | 6.0 | 0.0 | 40.0% | 8.0 | 8.0 | 0.0 | 50.0% |
Dividend per Share | 0.0 | 0.0 | 1.0 | 0.0% | 0.0 | 0.0 | 3.0 | 0.0% | 0.0 | 0.0 | 5.0 | 0.0% | 0.0 | 0.0 | 10.0 | 0.0% | 0.0 | 0.0 | 16.0 | 0.0% |
Total Gains per Share | 0.0 | 1.0 | 0.0 | 0.0% | 1.0 | 2.0 | 0.0 | 33.3% | 2.0 | 3.0 | 0.0 | 40.0% | 4.0 | 6.0 | 0.0 | 40.0% | 8.0 | 8.0 | 0.0 | 50.0% |
Fundamentals of BioLight Life Sciences Ltd
About BioLight Life Sciences Ltd
- https://bio-light.co.il
- Biotechnology
- 5
- Atidim Park Tel Aviv, Tel Aviv, Israel, 6158101
Google Maps Bing Maps
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.
Fundamental data was last updated by Penke on 2023-09-29 02:32:05.
Financial Health
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge loss. | ||
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is just able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its debts by selling its assets. | ||
The company is very able to pay all its debts with equity. |
Valuation
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is cheap. | ||
Based on the earnings, the company is expensive. | ||
Based on how much money comes from the company's main activities, the company is expensive. |
1.1. Profitability of BioLight Life Sciences Ltd.
1.1. Profitability
1.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
- A Net Profit Margin of -12,455.6% means that -124.56 for each 1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 12,733.3%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -9,071.2%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -7,462.9%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -12,455.6% | TTM | -12,455.6% | 0.0% | |
TTM | -12,455.6% | YOY | 12,733.3% | -25,188.9% | |
TTM | -12,455.6% | 5Y | -9,071.2% | -3,384.4% | |
5Y | -9,071.2% | 10Y | -7,462.9% | -1,608.3% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -175.6%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -215.7%. trending down. -2
1.1.2. Return on Assets
- Above 5% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
- -13.8% Return on Assets means that BioLight Life Sciences Ltd generated -0.14 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 0.6%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 4.4%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -25.2%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -13.8% | TTM | -13.8% | 0.0% | |
TTM | -13.8% | YOY | 0.6% | -14.4% | |
TTM | -13.8% | 5Y | 4.4% | -18.1% | |
5Y | 4.4% | 10Y | -25.2% | +29.6% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -12.0%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -11.7%. trending down. -2
1.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
- -14.8% Return on Equity means BioLight Life Sciences Ltd generated -0.15 for each 1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 0.6%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 4.9%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -74.7%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -14.8% | TTM | -14.8% | 0.0% | |
TTM | -14.8% | YOY | 0.6% | -15.4% | |
TTM | -14.8% | 5Y | 4.9% | -19.6% | |
5Y | 4.9% | 10Y | -74.7% | +79.5% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -14.7%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -14.3%. trending down. -2
1.2. Operating Efficiency of BioLight Life Sciences Ltd.
1.2. Operating Efficiency
1.2.1. Operating Margin
- Measures how much profit BioLight Life Sciences Ltd makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
- An Operating Margin of 0.0% means the company generated 0.00 for each 1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of BioLight Life Sciences Ltd:
- The MRQ is 0.0%. The data is not here.
Trends
- The 10Y is -43,757.9%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | - | 0.0% | |
TTM | - | YOY | -353,433.3% | +353,433.3% | |
TTM | - | 5Y | -78,844.8% | +78,844.8% | |
5Y | -78,844.8% | 10Y | -43,757.9% | -35,086.8% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -334.9%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -209.9%. trending up. +2
1.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 164.84 means that the operating costs are 164.84 for each 1 in net sales.
Let's take a look of the Operating Ratio trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 3,535.333. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 820.310. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 454.409. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 164.841 | TTM | 164.841 | 0.000 | |
TTM | 164.841 | YOY | 3,535.333 | -3,370.492 | |
TTM | 164.841 | 5Y | 820.310 | -655.469 | |
5Y | 820.310 | 10Y | 454.409 | +365.900 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.987. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 3.255. trending up. -2
1.3. Liquidity of BioLight Life Sciences Ltd.
1.3. Liquidity
1.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 7.11 means the company has 7.11 in assets for each 1 in short-term debts.
Let's take a look of the Current Ratio trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 15.379. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 13.286. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 9.079. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 7.107 | TTM | 7.107 | 0.000 | |
TTM | 7.107 | YOY | 15.379 | -8.272 | |
TTM | 7.107 | 5Y | 13.286 | -6.179 | |
5Y | 13.286 | 10Y | 9.079 | +4.207 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 4.061. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 4.617. trending up. +2
1.3.2. Quick Ratio
- Above 1 is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
- A Quick Ratio of 1.18 means the company can pay off 1.18 for each 1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 0.039. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 2.143. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 1.279. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.178 | TTM | 1.178 | 0.000 | |
TTM | 1.178 | YOY | 0.039 | +1.138 | |
TTM | 1.178 | 5Y | 2.143 | -0.965 | |
5Y | 2.143 | 10Y | 1.279 | +0.864 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.799. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 4.383. trending down. -2
1.4. Solvency of BioLight Life Sciences Ltd.
1.3. Liquidity
1.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare BioLight Life Sciences Ltd to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.06 means that BioLight Life Sciences Ltd assets are financed with 5.8% credit (debt) and the remaining percentage (100% - 5.8%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 0.043. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.081. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 0.259. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.058 | TTM | 0.058 | 0.000 | |
TTM | 0.058 | YOY | 0.043 | +0.015 | |
TTM | 0.058 | 5Y | 0.081 | -0.022 | |
5Y | 0.081 | 10Y | 0.259 | -0.178 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.325. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.321. trending down. +2
1.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
- A Debt to Equity ratio of 6.2% means that company has 0.06 debt for each 1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 0.045. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.088. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 0.688. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.062 | TTM | 0.062 | 0.000 | |
TTM | 0.062 | YOY | 0.045 | +0.017 | |
TTM | 0.062 | 5Y | 0.088 | -0.025 | |
5Y | 0.088 | 10Y | 0.688 | -0.601 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.366. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.377. trending down. +2
2. Market Valuation of BioLight Life Sciences Ltd
2.1. Earnings Per Share
2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
- A PE ratio of -3.97 means the investor is paying -3.97 for every 1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 138.246. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 25.869. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 9.499. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -3.295 | MRQ | -3.966 | +0.671 | |
MRQ | -3.966 | TTM | -3.966 | 0.000 | |
TTM | -3.966 | YOY | 138.246 | -142.211 | |
TTM | -3.966 | 5Y | 25.869 | -29.835 | |
5Y | 25.869 | 10Y | 9.499 | +16.370 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.424. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -2.620. trending down. +2
2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of BioLight Life Sciences Ltd:
- The EOD is -2.683. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -3.229. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is -3.229. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
- The YOY is -4.958. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -3.192. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is -4.207. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -2.683 | MRQ | -3.229 | +0.546 | |
MRQ | -3.229 | TTM | -3.229 | 0.000 | |
TTM | -3.229 | YOY | -4.958 | +1.729 | |
TTM | -3.229 | 5Y | -3.192 | -0.036 | |
5Y | -3.192 | 10Y | -4.207 | +1.015 |
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.268. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -3.687. trending up. -2
2. Book Value per Share
2.3. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 0.58 means the investor is paying 0.58 for each 1 in book value.
Let's take a look of the Price to Book Ratio trends of BioLight Life Sciences Ltd:
Trends
- The YOY is 0.860. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 0.670. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 3.599. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 0.482 | MRQ | 0.580 | -0.098 | |
MRQ | 0.580 | TTM | 0.580 | 0.000 | |
TTM | 0.580 | YOY | 0.860 | -0.280 | |
TTM | 0.580 | 5Y | 0.670 | -0.091 | |
5Y | 0.670 | 10Y | 3.599 | -2.929 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 1.970. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 2.140. trending down. +2
2. Total Gains per Share
3. Summary
3.1. Key Performance Indicators
The key performance indicators of BioLight Life Sciences Ltd compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | -168.807 | -168.807 | 0% | 28.626 | -690% | 199.557 | -185% | 35.737 | -572% |
Book Value Per Share | - | - | 1173.278 | 1173.278 | 0% | 1342.084 | -13% | 1403.593 | -16% | 962.598 | +22% |
Current Ratio | - | - | 7.107 | 7.107 | 0% | 15.379 | -54% | 13.286 | -47% | 9.079 | -22% |
Debt To Asset Ratio | - | - | 0.058 | 0.058 | 0% | 0.043 | +36% | 0.081 | -28% | 0.259 | -78% |
Debt To Equity Ratio | - | - | 0.062 | 0.062 | 0% | 0.045 | +38% | 0.088 | -29% | 0.688 | -91% |
Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Eps | - | - | -171.473 | -171.473 | 0% | 8.347 | -2154% | 139.621 | -223% | -149.326 | -13% |
Free Cash Flow Per Share | - | - | -210.610 | -210.610 | 0% | -232.768 | +11% | -312.982 | +49% | -442.274 | +110% |
Free Cash Flow To Equity Per Share | - | - | -210.610 | -210.610 | 0% | -212.773 | +1% | -111.808 | -47% | -86.342 | -59% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% |
Intrinsic Value_10Y_max | - | - | 996.514 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -756.015 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -171.887 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -255.767 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -309.350 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -617.120 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | -197.133 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -809.821 | - | - | - | - | - | - | - | - |
Market Cap | 2585575600.000 | -20% | 3111843200.000 | 3111843200.000 | 0% | 5280980960.000 | -41% | 4330953536.000 | -28% | 8986606172.780 | -65% |
Net Profit Margin | - | - | -124.556 | -124.556 | 0% | 127.333 | -198% | -90.712 | -27% | -74.629 | -40% |
Operating Margin | - | - | - | - | 0% | -3534.333 | 0% | -788.448 | 0% | -437.579 | 0% |
Operating Ratio | - | - | 164.841 | 164.841 | 0% | 3535.333 | -95% | 820.310 | -80% | 454.409 | -64% |
Pb Ratio | 0.482 | -20% | 0.580 | 0.580 | 0% | 0.860 | -33% | 0.670 | -14% | 3.599 | -84% |
Pe Ratio | -3.295 | +17% | -3.966 | -3.966 | 0% | 138.246 | -103% | 25.869 | -115% | 9.499 | -142% |
Price Per Share | 565.000 | -20% | 680.000 | 680.000 | 0% | 1154.000 | -41% | 946.400 | -28% | 1963.753 | -65% |
Price To Free Cash Flow Ratio | -2.683 | +17% | -3.229 | -3.229 | 0% | -4.958 | +54% | -3.192 | -1% | -4.207 | +30% |
Price To Total Gains Ratio | -3.347 | +17% | -4.028 | -4.028 | 0% | 40.313 | -110% | 5.712 | -171% | 5.339 | -175% |
Quick Ratio | - | - | 1.178 | 1.178 | 0% | 0.039 | +2893% | 2.143 | -45% | 1.279 | -8% |
Return On Assets | - | - | -0.138 | -0.138 | 0% | 0.006 | -2412% | 0.044 | -415% | -0.252 | +83% |
Return On Equity | - | - | -0.148 | -0.148 | 0% | 0.006 | -2445% | 0.049 | -402% | -0.747 | +406% |
Total Gains Per Share | - | - | -168.807 | -168.807 | 0% | 28.626 | -690% | 199.557 | -185% | 35.737 | -572% |
Usd Book Value | - | - | 13938443.200 | 13938443.200 | 0% | 15943853.200 | -13% | 16674575.280 | -16% | 11435587.680 | +22% |
Usd Book Value Change Per Share | - | - | -0.438 | -0.438 | 0% | 0.074 | -690% | 0.518 | -185% | 0.093 | -572% |
Usd Book Value Per Share | - | - | 3.046 | 3.046 | 0% | 3.484 | -13% | 3.644 | -16% | 2.499 | +22% |
Usd Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Eps | - | - | -0.445 | -0.445 | 0% | 0.022 | -2154% | 0.362 | -223% | -0.388 | -13% |
Usd Free Cash Flow | - | - | -2502024.800 | -2502024.800 | 0% | -2765259.200 | +11% | -3718198.880 | +49% | -5254174.200 | +110% |
Usd Free Cash Flow Per Share | - | - | -0.547 | -0.547 | 0% | -0.604 | +11% | -0.813 | +49% | -1.148 | +110% |
Usd Free Cash Flow To Equity Per Share | - | - | -0.547 | -0.547 | 0% | -0.552 | +1% | -0.290 | -47% | -0.224 | -59% |
Usd Market Cap | 6712154.258 | -20% | 8078344.947 | 8078344.947 | 0% | 13709426.572 | -41% | 11243155.379 | -28% | 23329229.625 | -65% |
Usd Price Per Share | 1.467 | -20% | 1.765 | 1.765 | 0% | 2.996 | -41% | 2.457 | -28% | 5.098 | -65% |
Usd Profit | - | - | -2037081.200 | -2037081.200 | 0% | 99167.200 | -2154% | 1658688.240 | -223% | -1773976.600 | -13% |
Usd Revenue | - | - | 16354.800 | 16354.800 | 0% | 778.800 | +2000% | 211885.520 | -92% | 254797.400 | -94% |
Usd Total Gains Per Share | - | - | -0.438 | -0.438 | 0% | 0.074 | -690% | 0.518 | -185% | 0.093 | -572% |
EOD | +3 -5 | MRQ | TTM | +0 -0 | YOY | +11 -21 | 5Y | +10 -22 | 10Y | +14 -18 |
3.2. Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -3.295 | |
Price to Book Ratio (EOD) | Between | 0-1 | 0.482 | |
Net Profit Margin (MRQ) | Greater than | 0 | -124.556 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 1.178 | |
Current Ratio (MRQ) | Greater than | 1 | 7.107 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.058 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.062 | |
Return on Equity (MRQ) | Greater than | 0.15 | -0.148 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.138 | |
Total | 5/10 (50.0%) |
3.3. Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 38.941 | |
Ma 20 | Greater than | Ma 50 | 585.370 | |
Ma 50 | Greater than | Ma 100 | 621.300 | |
Ma 100 | Greater than | Ma 200 | 617.519 | |
Open | Greater than | Close | 560.000 | |
Total | 1/5 (20.0%) |
Latest Balance Sheet
Balance Sheet of 2022-12-31. Currency in ILS. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 3,319 |
Total Stockholder Equity | + 53,168 |
Total Assets | = 57,011 |
Assets
Total Current Assets
Long-term Assets
Long-term Assets (as reported) | 38,987 |
---|---|
Long-term Assets (calculated) | 0 |
+/- | 38,987 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt | 527 |
Long-term Liabilities (as reported) | 783 |
---|---|
Long-term Liabilities (calculated) | 527 |
+/- | 256 |
Total Stockholder Equity
Total Stockholder Equity (as reported) | 53,168 |
---|---|
Total Stockholder Equity (calculated) | 0 |
+/- | 53,168 |
Other
Capital Stock | 11,443 |
Common Stock Shares Outstanding | 4,576 |
Net Invested Capital | 53,168 |
Net Working Capital | 15,488 |
Balance Sheet
Currency in ILS. All numbers in thousands.
Trend | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2006-12-31 | 2005-12-31 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 57,011 | 64,171 | 64,829 | 74,951 | 90,282 | 24,763 | 35,313 | 63,271 | 40,434 | 34,332 | 41,891 | 29,632 | 10,139 | 22,489 | 48,163 | 20,390 | ||||||||||||||||
> Total Current Assets |
| 18,024 | 34,004 | 51,460 | 40,712 | 62,513 | 19,860 | 30,031 | 53,439 | 32,432 | 21,009 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
Cash And Cash Equivalents |
| 13,392 | 33,467 | 29,988 | 35,346 | 43,058 | 15,355 | 25,474 | 50,697 | 22,196 | 17,716 | 28,497 | 4,751 | 5,413 | 9,624 | 5,072 | 2,310 | ||||||||||||||||
Short-term Investments |
| 2,987 | 0 | 19,961 | 4,604 | 387 | 412 | 417 | 385 | 6,408 | 185 | 610 | 7,029 | 2,158 | 10,996 | 38,750 | 17,333 | ||||||||||||||||
Net Receivables |
| 0 | 87 | 92 | 565 | 725 | 512 | 1,669 | 866 | 813 | 1,584 | 959 | 237 | 308 | 445 | 126 | 130 | ||||||||||||||||
Inventory |
| 0 | 0 | 0 | 0 | 0 | 2,846 | 2,494 | 991 | 976 | 1,055 | 583 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
> Long-term Assets |
| 38,987 | 30,167 | 13,369 | 34,239 | 27,769 | 4,903 | 5,282 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
Property Plant Equipment |
| 0 | 3,257 | 3,163 | 714 | 304 | 922 | 1,287 | 743 | 819 | 911 | 947 | 1,663 | 1,790 | 1,095 | 176 | 0 | ||||||||||||||||
Goodwill |
| 0 | 112 | 112 | 3,873 | 3,873 | 3,873 | 3,873 | 3,873 | 3,873 | 4,678 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
Long Term Investments |
| 0 | 0 | 0 | 0 | 20,006 | 0 | 0 | 79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
Intangible Assets |
| 0 | 37 | 37 | 37 | 37 | 37 | 37 | 2,996 | 7,106 | 12,307 | 0 | 0 | 0 | 0 | 994 | 263 | ||||||||||||||||
Other Assets |
| 0 | 946 | 0 | 1,003 | 3,549 | 71 | 85 | 2,141 | 77 | 105 | 38 | 52 | 100 | 90 | 40 | 0 | ||||||||||||||||
> Total Liabilities |
| 3,319 | 2,754 | 4,722 | 6,804 | 12,486 | 16,732 | 18,903 | 16,210 | 14,696 | 12,223 | 4,553 | 6,085 | 7,417 | 9,182 | 40,154 | 2,689 | ||||||||||||||||
> Total Current Liabilities |
| 2,536 | 2,211 | 2,561 | 3,571 | 5,021 | 7,259 | 6,988 | 6,605 | 6,552 | 4,898 | 1,874 | 3,566 | 3,553 | 3,645 | 2,312 | 1,862 | ||||||||||||||||
Accounts payable |
| 301 | 146 | 580 | 221 | 1,386 | 737 | 2,776 | 873 | 943 | 1,365 | 209 | 391 | 639 | 550 | 331 | 74 | ||||||||||||||||
Other Current Liabilities |
| 0 | 0 | 1,522 | 161 | 211 | 837 | 794 | 859 | 5,609 | 3,533 | 1,665 | 3,175 | 2,914 | 3,095 | 1,980 | 1,787 | ||||||||||||||||
> Long-term Liabilities |
| 783 | 543 | 2,161 | 3,233 | 7,465 | 9,473 | 11,915 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
Capital Lease Obligations Min Short Term Debt |
| 527 | 443 | 929 | 450 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
Long-term Liabilities Other |
| 0 | 0 | 0 | 2,225 | 5,177 | 9,273 | 11,915 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
> Total Stockholder Equity |
| 53,168 | 60,702 | 59,217 | 68,863 | 82,331 | 6,100 | 10,841 | 34,644 | 28,403 | 12,573 | 38,285 | 22,882 | 0 | 4,964 | 8,008 | 17,701 | ||||||||||||||||
Common Stock |
| 0 | 11,401 | 11,359 | 11,359 | 11,359 | 9,088 | 6,519 | 6,519 | 5,215 | 3,423 | 3,423 | 1,765 | 917 | 701 | 331 | 289 | ||||||||||||||||
Retained Earnings Total Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Accumulated Other Comprehensive Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Other Stockholders Equity |
| 0 | 9,719 | 8,856 | 5,289 | 6,166 | 6,390 | 10,040 | 18,591 | 20,595 | 14,217 | 0 | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
Currency in ILS. All numbers in thousands.
Cash Flow
Currency in ILS. All numbers in thousands.
Income Statement
Currency in ILS. All numbers in thousands.